Axsome Therapeutics, Inc. Stock News

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Asim Rana - Truist Secur...

Axsome (AXSM) Q2 Revenue Soars 72%

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI ® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO ® launched June 10 th , with 2Q 202...

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file AXS-14 and Sunosi's failure in MDD studies, but ADHD data for Sunosi is encouraging. I estimate $3bn in peak revenues by the mid-2030s, which supports a Buy rating despite management's more ambitio...

Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year.

Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conferenc...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-s...